诺华投资 2.56 亿美元扩建新加坡生物制药工厂，以满足亚洲不断增长的需求，创造 100 个就业机会并采用数字/自动化。 Novartis invests $256m to expand Singapore biopharmaceutical plant for Asia's growing demand, creating 100 jobs and using digital/automation.

诺华投资 2.56 亿美元扩建其新加坡生物制药制造工厂，以满足亚洲不断增长的需求。 Novartis invests US$256 million to expand its Singapore biopharmaceutical manufacturing plant, addressing the growing demand in Asia. 此次扩建将创造 100 个高技能岗位，重点是生产治疗性抗体药物。 The expansion will generate 100 high-skilled jobs, focusing on manufacturing therapeutic antibody drugs. 将部署数字和自动化解决方案，以提高生产力、提高效率并提高员工技能。 Digital and automation solutions will be deployed to enhance productivity, improve efficiency, and upskill the workforce. 该站点预计将于 2026 年初投入运营。 The site is expected to be operational by early 2026.